抗视网膜脉络膜新生血管性疾病治疗药物靶点的研究进展  

Research progress on drug targets for anti-retinal and choroidal neovascular diseases

作　　者：刘辰 方思尹 顾操 吴晋晖 LIU Chen;FANG Si-yin;GU Cao;WU Jin-hui(Department of Ophthalmology, the First Affiliated Hospital, Navy Military Medical University, Shanghai 200433;Department of Ophthalmology, the Third Affiliated Hospital, Navy Military Medical University,Shanghai 200438, China)

机构地区：[1]海军军医大学第一附属医院眼科,上海200433 [2]海军军医大学第三附属医院眼科,上海200438

出　　处：《基础医学与临床》2022年第2期325-329,共5页Basic and Clinical Medicine

基　　金：上海市浦江人才项目(17PJD041);海军军医大学,未来战争医学防护技术研发专项(19WLMS-03);上海市中医药管理局(ZHYY-ZXYJHZX-202024)。

摘　　要：新生血管性年龄相关性黄斑变性(nAMD)、糖尿病视网膜病变(DR)等眼底病继发形成新生血管,是致盲的重要原因之一。抗血管内皮生长因子(VEGF)治疗是当前主流疗法。但仍存在部分患者对其疗效欠佳等局限,临床仍需要开发新的药物靶点。The appearance of new blood vessels in the neovascular age-related macular degeneration(nAMD),diabetic retinopathy(DR),and other ocular diseases is one of the important reasons for blindness.Anti-vascular endothelial growth factor(VEGF)drugs are the current mainstream.However,some patients have poor efficacy and other adverse reactions.There is still a need to develop new drugs.

关 键 词：视网膜 脉络膜 新生血管 药物靶点 

分 类 号：R774.1[医药卫生—眼科]